The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Antihypertensive Drug Therapy and the Initiation of Treatment for Diabetes Mellitus

Jerry H. Gurwitz, MD; Rhonda L. Bohn, MPH; Robert J. Glynn, ScD; Mark Monane, MD, MS; Helen Mogun, MS; and Jerry Avorn, MD
[+] Article, Author, and Disclosure Information

From the Program for the Analysis of Clinical Strategies, Brigham and Women's Hospital and Harvard Medical School; the Hebrew Rehabilitation Center for Aged, Boston, Massachusetts. Requests for Reprints: Jerry H. Gurwitz, MD, Program for the Analysis of Clinical Strategies, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115. Acknowledgments: The authors thank Linda Morrow, MD, and Nananda Col, MD, for their helpful reviews of the manuscript; and Rita Bloom and Igor Choodnovskiy for assistance in preparing the manuscript. Grant Support: In part by grants from the Medications and Aging Program of the John A. Hartford Foundation and the National Institute on Aging (AG-08812). Dr. Gurwitz is the recipient of a Clinical Investigator Award (K08 AG00510) from the National Institute on Aging, and Dr. Monane is the recipient of a Merck Fellowship in Geriatric Clinical Pharmacology from the American Federation for Aging Research.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1993;118(4):273-278. doi:10.7326/0003-4819-118-4-199302150-00005
Text Size: A A A

Objective: To quantify the risk for the occurrence of hyperglycemia requiring initiation of therapy among patients taking various antihypertensive regimens.

Design: Case-control study.

Setting: New Jersey Medicaid program.

Patients: The study included New Jersey Medicaid enrollees 35 years of age or older. The 11 855 case patients were newly started on a hypoglycemic agent (oral agent or insulin) between 1981 and 1990. The 11 855 controls were selected randomly from among other Medicaid enrollees.

Measurements and Main Results: The frequency of initiation of hypoglycemic therapy was increased for users of virtually all antihypertensive agents relative to nonusers after adjustment for age, gender, race, nursing home residency, number of days hospitalized, total number of prescriptions, and selected medication exposures. The estimated relative risk for initiation of hypoglycemic therapy was 1.40 for patients receiving thiazide diuretics (95% CI, 1.26 to 1.58) and ranged from 1.56 to 1.77 for patients receiving other antihypertensive medications, depending on the medication category. A higher risk was associated with multiple-agent regimens, whether they excluded a thiazide diuretic (odds ratio, 1.76; CI, 1.49 to 2.07) or included one (odds ratio, 1.93; CI, 1.75 to 2.13). When the analysis was restricted to users of antihypertensive agents (n = 8005), the risk associated with other single-agent antihypertensive regimens was not significantly different from that associated with thiazide diuretics. However, patients receiving multiple-agent regimens continued to be at increased risk for hyperglycemia requiring hypoglycemic therapy relative to those who used thiazide diuretic therapy alone.

Conclusion: The association between antihypertensive therapy and the initiation of treatment for diabetes mellitus is more closely related to the intensity of therapy than to the individual agent used. Our data do not support the hypothesis that thiazide diuretics are more strongly associated with the initiation of hypoglycemic therapy than are other antihypertensive agents.


Grahic Jump Location
Figure 1.
The risk for development of hyperglycemia requiring treatment in users of antihypertensive drugs relative to nonusers.

Circles indicate point estimates (odds ratios [ORs]). Horizontal bars indicate 95% CIs. Odds ratio for nonusers = 1.0. ACE = angiotensin-converting enzyme (inhibitors).

Grahic Jump Location
Grahic Jump Location
Figure 2.
Risk associated with receiving hypoglycemic therapy among users of antihypertensive drugs relative to users of thiazides.

Circles indicate point estimates (odds ratios [ORs]). Horizontal bars indicate 95% CIs. The odds ratio for thiazide = 1.0. ACE = angiotensin-converting enzyme (inhibitors).

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Nephrology Update: Chronic Kidney Disease. FP Essent 2016;444():18-22.
Complication in diabetic nephropathy. Diabetes Metab Syndr Published online Jun 18, 2016;
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.